Company intelligence / Profile preview

Senz Oncology

Melbourne/Eltham, Victoria, Australia

Ownership: Private
Development stage: Other

Overview

Senz Oncology is advancing EO1001 (APL-122), a first-in-class oral irreversible pan-ErbB inhibitor with promising CNS penetration, in a Phase 1-2 clinical trial for ErbB-positive cancers including patients with CNS involvement.[3] The company previously initiated a Phase 1-2 trial of VAL-1000 in acute leukemias, which was later withdrawn.[3]

Therapeutic areas: Oncology
Modalities: Small moleculeIrreversible tyrosine kinase inhibitor
Industry: Biotech

Partnerships

NewGen Therapeutics

Beyond the preview

Go deeper on Senz Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Senz Oncology.

Explore the full profile